公开(公告)号：US20160311917A1

公开(公告)日：2016-10-27

申请号：US15105082

申请日：2014-12-19

Applicant: Gregory Beatty ,  Boris Engels ,  Neeraja Idamakanti ,  Carl H. June ,  Andreas Loew ,  Huijuan Song ,  Qilong Wu

Inventor： Gregory Beatty ,  Boris Engels ,  Neeraja Idamakanti ,  Carl H. June ,  Andreas Loew ,  Huijuan Song ,  Qilong Wu

IPC: C07K16/30 ,  C07K14/705 ,  C07K14/715 ,  C12N5/0783 ,  A61K39/395 ,  A61K48/00 ,  A61K38/17 ,  C12N15/85 ,  A61K31/436 ,  C07K14/725

CPC classification number: C07K16/30 ,  A61K31/436 ,  A61K38/00 ,  A61K38/1774 ,  A61K38/1793 ,  A61K39/0011 ,  A61K39/39558 ,  A61K48/0058 ,  A61K2039/505 ,  A61K2039/5158 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/7151 ,  C07K16/303 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/74 ,  C12N5/0638 ,  C12N15/85 ,  C12N15/86 ,  C12N2740/15041

Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.

Abstract translation: 提供了用于治疗与间皮素表达相关的疾病的组合物和方法。 还提供了对间皮素特异性的嵌合抗原受体（CAR），编码它的载体和包含间皮素CAR的重组T细胞。 还提供了施用表达包含间皮素结合结构域的CAR的遗传修饰的T细胞的方法。

公开(公告)号：US20180334490A1

公开(公告)日：2018-11-22

申请号：US15529246

申请日：2015-12-02

Applicant: Jennifer Brogdon ,  Gregory Beatty ,  David Glass ,  Carl H. June ,  Joan Mannick ,  Michael Milone ,  Leon Murphy ,  Gabriela Plesa ,  Huijuan Song ,  Qilong Wu ,  Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Jennifer Brogdon ,  Gregory Beatty ,  David Glass ,  Carl H. June ,  Joan Mannick ,  Michael Milone ,  Leon Murphy ,  Gabriela Plesa ,  Huijuan Song ,  Qilong Wu

IPC: C07K14/725 ,  A61P35/00 ,  A61K35/17 ,  C07K14/705 ,  C07K16/28 ,  C07K16/30 ,  A61K45/06 ,  A61K38/17 ,  A61K39/395 ,  A61K31/675 ,  A61K31/436 ,  A61N5/10

CPC classification number: C07K14/7051 ,  A61K31/436 ,  A61K31/675 ,  A61K35/00 ,  A61K35/17 ,  A61K38/177 ,  A61K38/1774 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/5256 ,  A61K2039/545 ,  A61N5/10 ,  A61N2005/1098 ,  A61P35/00 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/303 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/33 ,  C07K2319/70

Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to the methods of preconditioning a subject, e.g., by depleting B cells in combination with the use of a cell comprising a chimeric antigen receptor (CAR) that targets a tumor antigen as described herein. The methods for preconditioning the subject described herein include using a cell comprising a CAR that targets a B cell antigen as described herein.

公开(公告)号：US20170260268A1

公开(公告)日：2017-09-14

申请号：US15511973

申请日：2015-09-17

Applicant: Gregory BEATTY ,  Boris ENGELS ,  Neeraja IDAMAKANTI ,  Carl H JUNE ,  Andreas LOEW ,  Michael C. MILONE ,  Huijuan SONG ,  Enxiu WANG ,  Qilong WU

Inventor： Gregory Beatty ,  Boris Engels ,  Neeraja Idamakanti ,  Carl H. June ,  Andreas Loew ,  Michael Milone ,  Huijuan Song ,  Enxiu Wang ,  Qilong Wu

IPC: C07K16/28 ,  C07K14/725 ,  C07K16/30 ,  C12N5/0783 ,  A61K35/17 ,  C07K14/74 ,  C07K14/705

CPC classification number: C07K16/28 ,  A61K35/17 ,  C07K14/705 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70535 ,  C07K14/70539 ,  C07K14/7056 ,  C07K14/70596 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/74 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/70 ,  C07K2319/74 ,  C12N5/0636 ,  C12N2510/00

Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).

公开(公告)号：US20060073159A1

公开(公告)日：2006-04-06

申请号：US11137253

申请日：2005-05-25

Applicant: Robert Vonderheide ,  Gregory Beatty ,  Christina Coughlin

Inventor： Robert Vonderheide ,  Gregory Beatty ,  Christina Coughlin

IPC: A61K39/00 ,  A61K48/00

CPC classification number: A61K39/001 ,  A61K2039/5156 ,  A61K2039/53 ,  C12N5/0636

Abstract: The present invention encompasses compositions and methods for activating, stimulating and isolating antigen-specific T cells. The present invention also relates to compositions of antigen-specific T cells and methods of their use in the treatment and prevention of cancer, infectious diseases, autoimmune diseases, immune disfunction related to aging, or any other disease state where antigen-specific T cells are desired for treatment.

Abstract translation: 本发明包括用于激活，刺激和分离抗原特异性T细胞的组合物和方法。 本发明还涉及抗原特异性T细胞的组合物及其用于治疗和预防癌症，感染性疾病，自身免疫性疾病，与衰老有关的免疫功能障碍或其中抗原特异性T细胞的任何其它疾病状态的方法 需要治疗。